Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

THE ASSESSMENT OF ROM AND RMM COMBINED CHEMOTHERAPY OUTCOME ON AN EXPERIMENTAL LEPROSY IN MICE FOOTPAD

DOI: https://doi.org/10.29296/25877313-2022-12-09
Download full text PDF
Issue: 
12
Year: 
2022

V.S. Solomka
Dr.Sc. (Biol.), State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia (Moscow, Russia)
D.A. Verbenko
Ph.D. (Biol.), State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia (Moscow, Russia)
E-mail: verbenko@cnikvi.ru
A.A. Nikonorov
Dr.Sc. (Med.), State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia (Moscow, Russia)
A.E. Karamova
Ph.D. (Med.), State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia (Moscow, Russia)

Relevance. The leprosy standard combined therapy recommended by the World Health Organization includes: dapsone, rifampicin and clofazimine. In the Russian Federation however only two of them are registered, making full-fledged leprosy patients therapy impossible. Alternative leprosy treatment regimens with various combinations of rifampicin and fluoroquinolones have been proposed, eg. rifampicin, ofloxacin and minocycline (ROM) or rifam-picin, moxifloxacin, and minocycline (RMM), but the assessment of their effectiveness is ambiguous. The purpose of study is the assessment of ROM and RMM combination leprosy drug therapy outcomes on an experimental disease model - in the paw pads of mice. Material and methods. the experiment was performed on 50 BALB/cNude mice. Infectious material was obtained from a patient of the Sergiev Po-sad Branch of the Federal State Budgetary Institution "GNTSDK" of the Ministry of Health of the Russian Federation diagnosed with "Lepromatous lepro-sy" (A.30.5 according to ICD10). The reproduction of the experimental model of the disease was carried out according to the Shepard model at mouse paw pads. The presence of M. leprae was assessed by real-time PCR using the multicopy species-specific region of the M. leprae genome RLEP. The experiment included the stages of an experimental leprosy reproduction in mice paw pads and subsequent treatment using ROM and RMM combination chemotherapy regimens. Results. The obtained results demonstrate the high efficacy for both ROM and RMM combination chemotherapy regimens for the treatment of experi-mental leprosy in mice. Conclusions. The obtained results of high efficiency of experimental leprosy chemotherapy with ROM or RMM regimens paw the way to recommend conducting clinical trials of these regimens in leprosy patients.

Keywords: 
leprosy
laboratory animals
combination drug therapy
therapy outcomes
fluoroquinolones
rifampicin
monofloxacin
ofloxacin
minocycline

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Guidelines for the diagnosis, treatment and prevention of lep-rosy. ISBN: 978-92-9022-6383. World Health Organization. 2018. 87 p.
  2. Kubanov A.A., Karamova A.E., Vorontsova A.A., Kalinina P.A. Farmakoterapija lepry. Vestnik dermatologii i venerologii. 2016, 92 (4): 12–19. doi: 10.25208/0042-4609-2016-92-4-12-19.
  3. Ji B., Sow S., Perane E., Lienhardt C., Diderot V., Grosset J. Bactericidal activity of a single-dose combination of ofloxa-cin plus minocycline, with or without rifampin, against Myco-bacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 1988; 42(5): 11151120. doi: 10.1128/AAC.42.5.1115.
  4. Pardillo F.E.F., Burgos J., Fajardo T.T., Dela Cruz E., Abalos R.M., Paredes R.M.D., et al. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother. 2008; 52(9): 3113–3117. doi: 10.1128/AAC.01162-07.
  5. Ji B., Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr. Rev. 2000; 71: 81–87. doi: 10.5935/0305-7518.20000074.
  6. Lazo-Porras M., Prutsky G.J., Barrionuevo P., Tapia J.C., Ugar-ti-Gil C., Ponce O.J., et al. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. BMC Infect Dis. 2020; 20(1): 62. doi: 10.1186/s12879-019-4665-0.
  7. Shepard C.C. The experimental disease that follows the in-jection of human leprosy bacilli into foot-pads of mice. J. Exp. Med. 1960; 112(3): 445–454.
  8. Karamova A.E., Semenova V.G., Verbenko D.A., Obraztsova O.A., Vanchugova H.M., Nikonorov A.A., Deryabin D.G., Solomka V.S., Kubanov A.A. Opyt jeksperi-mental'nogo modelirovanija lepry na myshah linij Balb/c, Balb/cNude, SVA i C57BL/6TNF-/-. Bjulleten' jeksperimental'noj biologii i mediciny. 2020; 169(6): 784–787. doi: 10.1007/s10517-020-04991-7.
  9. Lahiri R., Adams L.B. Cultivation and Viability Determination of Mycobacterium leprae. In: The International text-book of Leprosy. American Leprosy Missions. 2019. https://internationaltextbookofleprosy.org/.
  10. Kubanov A.A., Karamova A.E., Semenova V.G., Smoliannikova V.A., Nefedova M.A. Recidiv lepry, razvivshijsja posle prekrashhenija protivoleproznoj terapii. Vest-nik dermatologii i venerologii. 2016; 92(6): 66–72. doi: 10.25208/0042-4609-2016-92-6-66-72.
  11. Obrazcova O.A., Verbenko D.A., Karamova A.E., Semenova V.G., Kubanov A.A., Deryabin D.G. Sovershenstvovanie PCR-diagnostiki lepry putem amplifikacii vidospecifichnogo povtorjajushhegosja fragmenta genoma Mycobacterium leprae. Klinicheskaja laboratornaja diagnostika. 2018; 63(8): 511–516. doi: 10.18821/0869-2084-2018-63-8-511-516.